Your browser doesn't support javascript.
loading
Troponin is a useful marker in clinical decision making in hospitalized patients with COVID-19 infections.
Safarnezhad-Tameshkel, Fahimeh; Motamed, Nima; Karbalaie Niya, Mohammad Hadi; Perumal, Dhayaneethie; Rezaie, Nader; Izadi, Shirin; Ranjbar, Mitra; Yadollahzadeh, Mahdi; Behdad, Behnam; Hemmasi, Gholamreza; Kaveh, Vahid; Anoushirvani, Ali Arash; Malek, Mojtaba; Farahani, Behzad; Eskandari, Ramin; Panahi, Mahshid; Rahimi, Mandana; Emami, Sepideh; Zamani, Farhad; Farrokhpour, Mohsen.
Afiliación
  • Safarnezhad-Tameshkel F; Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Motamed N; Associate Professor, Department of Social Medicine, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
  • Karbalaie Niya MH; Assistant Professor, Gastrointestinal and Liver Diseases Research Center AND Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Perumal D; Assistant Professor, School of Science, Engineering and Computing, Kingston University, Kingston, United Kingdom.
  • Rezaie N; Associate Professor, Department of Pulmonology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
  • Izadi S; Assistant Professor, Department of Pulmonology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
  • Ranjbar M; Professor, Department of Infectious Diseases, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Yadollahzadeh M; Assistant Professor, Department of Internal Medicine, School of Medicine, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
  • Behdad B; Resident, Department of Internal Medicine, School of Medicine, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
  • Hemmasi G; Associate Professor, Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Kaveh V; Assistant Professor, Department of Hematology and Medical Oncology, School of Medicine, Iran University Medical Sciences, Tehran, Iran.
  • Anoushirvani AA; Associate Professor, Department of Hematology and Medical Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Malek M; Associate Professor, Research Center for Prevention of Cardiovascular Disease, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.
  • Farahani B; Assistant Professor, Department of Cardiology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
  • Eskandari R; Assistant Professor, Department of Cardiology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
  • Panahi M; Assistant Professor, Department of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Rahimi M; Assistant Professor, Department of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Emami S; Assistant Professor, Department of Cardiology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
  • Zamani F; Professor, Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Farrokhpour M; Assistant Professor, Department of Internal Medicine, School of Medicine, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
ARYA Atheroscler ; 17(5): 1-7, 2021 Sep.
Article en En | MEDLINE | ID: mdl-35686240
ABSTRACT

BACKGROUND:

COVID-19 was introduced by the World Health Organization (WHO) as a global pandemic. The disease manifestations ranges from a mild common cold to severe disease and death. It has a higher mortality rate in people with a history of comorbidities, including cardiovascular disease (CVD) and can also contribute to cardiac injury. This study was conducted to evaluate the relationship between troponin levels as a cardiac marker and adverse outcomes in this disease.

METHODS:

The study sample included 438 patients hospitalized with COVID-19; however, the troponin data of 6 patients were not available. The need to be admitted to the intensive care unit (ICU), and death were considered the adverse outcome in patients with COVID-19. Troponin levels were checked in all patients on day 1 and day 3 of hospitalization. Multiple logistic regression analysis was performed to determine whether there was an independent association between the adverse outcomes and troponin enzyme in hospitalized patients with COVID-19.

RESULTS:

The mean age of patients was 61.29 ± 15.84 years. Among the 432 patients tested on day 1 of hospitalization, 24 patients (5.6%) tested positive (Troponin 1), and among the 303 patients tested on day 3, 13 patients (4.3%) tested positive (Troponin 2). Based on our results, Troponin 1 showed an independent association with both death (3.008 [95%CI = 1.091-8.290]; P = 0.033) and need for ICU admission (8.499 [95%CI = 3.316-21.788]; P < 0.001) in multiple logistic regression analysis. Moreover, the status of Troponin 2 had an independent significant association with both death (4.159 [95%CI = 1.156-14.961]; P = 0.029) and ICU admission (7.796 [95%CI = 1.954-31.097]; P = 0.004).

CONCLUSION:

Troponin showed a significant association with adverse outcomes in people who were hospitalized with COVID-19. The periodical assessment of this enzyme from the time of hospitalization may improve the clinical decision making of clinicians.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: ARYA Atheroscler Año: 2021 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: ARYA Atheroscler Año: 2021 Tipo del documento: Article País de afiliación: Irán